Skip to main content
Clinical Trials/NCT01172899
NCT01172899
Unknown
Not Applicable

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Maastricht University Medical Center1 site in 1 country60 target enrollmentDecember 1, 2011
ConditionsObesity, Morbid

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity, Morbid
Sponsor
Maastricht University Medical Center
Enrollment
60
Locations
1
Primary Endpoint
Weight
Last Updated
4 years ago

Overview

Brief Summary

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Registry
clinicaltrials.gov
Start Date
December 1, 2011
End Date
December 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 14 to 16
  • Age and sex adjusted BMI \>40 kg/m2 or \>35 kg/m2 with associated co-morbidity.
  • \* Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.
  • \> 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria

  • Psychologically not suitable
  • Pre-menarche or bone age \<15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Outcomes

Primary Outcomes

Weight

Time Frame: 36 months

Weight loss, excess weight loss and loss of excess BMI.

Secondary Outcomes

  • Metabolic and endocrine changes(36 months)
  • Quality of life changes(36 months)
  • Behaviour changes(36 months)
  • Behavior towards food(36 months)
  • Non-alcoholic fatty liver disease(36 months)
  • Effects on sleep architecture(36 months)
  • Body composition(36 months)
  • Pubertal development(36 months)
  • Inflammatory status(36 months)
  • Cardiovascular abnormalities(36 months)
  • Operative complications(up to 36 months)
  • Brain development(36 months)
  • Physical activity(36 months)

Study Sites (1)

Loading locations...

Similar Trials